Emfo LLC Sells 3,436 Shares of Johnson & Johnson (NYSE:JNJ)

Emfo LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 63.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,941 shares of the company’s stock after selling 3,436 shares during the period. Emfo LLC’s holdings in Johnson & Johnson were worth $284,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Beacon Financial Advisory LLC boosted its holdings in Johnson & Johnson by 282.4% in the second quarter. Beacon Financial Advisory LLC now owns 8,322 shares of the company’s stock valued at $1,216,000 after acquiring an additional 6,146 shares during the last quarter. Aletheian Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 3.5% in the second quarter. Aletheian Wealth Advisors LLC now owns 7,458 shares of the company’s stock valued at $1,090,000 after buying an additional 250 shares during the period. Briaud Financial Planning Inc boosted its position in Johnson & Johnson by 9.4% during the second quarter. Briaud Financial Planning Inc now owns 1,153 shares of the company’s stock valued at $168,000 after acquiring an additional 99 shares during the last quarter. West Branch Capital LLC grew its holdings in Johnson & Johnson by 1.0% during the 2nd quarter. West Branch Capital LLC now owns 24,202 shares of the company’s stock worth $3,537,000 after acquiring an additional 245 shares during the period. Finally, Ballast Advisors LLC raised its position in shares of Johnson & Johnson by 0.8% in the 2nd quarter. Ballast Advisors LLC now owns 8,632 shares of the company’s stock worth $1,262,000 after acquiring an additional 70 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on JNJ shares. TD Cowen dropped their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ stock opened at $163.92 on Thursday. The company has a market capitalization of $394.50 billion, a PE ratio of 10.22, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The business’s fifty day moving average is $154.64 and its 200 day moving average is $153.31. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $165.83.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the business posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.